ArticleAmerican journal of preventive cardiology2025
Poland takes a lead in effective lipid disorders management healthcare programmes in Europe.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Time-Trends in Case-Fatality After Acute Myocardial Infarction Among Middle-Aged Lithuanian Adults, 2000-2023: Data from the Population-Based Kaunas Ischemic Heart Disease Register.Medicina (Kaunas, Lithuania) · 2026Article
- AJPC 2025 in review: A year of growth & clearer mandate for actionable prevention.American journal of preventive cardiology · 2026Article
- Cardiovascular disease in cancer patients: a neglected dimension of modern oncology.Archives of medical science : AMS · 2026Article
- Predictors of Escalation of Lipid-Lowering Therapy with Subanalysis of the Influence of Lipoprotein (a) on the Decision-Making Process.Diseases (Basel, Switzerland) · 2025Article
- The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now!Global heart · 2025Review
- 2025: The year in cardiovascular disease - the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?Archives of medical science : AMS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decade, Poland has introduced various healthcare programs and initiatives aimed at effectively managing and preventing lipid disorders, a leading risk factor for cardiovascular disease (CVD) affecting as many as 70 % of the population. Education plays a vital role, with the "Health Education" subject introduced in schools, patient education integrated into primary and secondary prevention programs, and lipidology certification available for healthcare professionals. Screening programs like "My Health" offer comprehensive health assessments, including lipid profiles and the first universal lipoprotein(a) screening for individuals aged 20 and older. A universal screening program for familial hypercholesterolemia (FH) has also been implemented for children at the age of 6. The KOS-Zawał program provides comprehensive, highly effective cardiology care for post-myocardial infarction patients. Additionally, recent results from the B101 drug program demonstrate unprecedented effectiveness of combination lipid-lowering therapy with PCSK9 inhibitors for patients with lipid disorders. These programs aim to improve early diagnosis, enhance therapy adherence, and ensure access to innovative treatments, ultimately reducing cardiovascular mortality. They may also serve as a valuable example for other countries looking to effectively prevent and combat this prevalent CVD risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.